Malignant neoplasm of commissure of lip
ICD-10 C00.6 · ICD-11 2B6B.0.1

Treatment of Larger, Advanced-Stage Malignant Neoplasm of the Commissure of Lip T3 / T4

Clinical Scenario

This protocol addresses malignant neoplasm of the commissure of the lip at T3 or T4 stage — tumours exceeding 4 cm in greatest dimension — where the extent of disease introduces significant reconstruction challenges and the disease may be inoperable.

Staging & Reconstruction Context

Larger lesions of the lip require more consideration with regard to reconstruction techniques. Five-year survival rates for surgically treated cases are approximately 75–80% at T1–T2 stage, dropping substantially to 40–50% for T3 and T4 tumours.

Treatment Approach (Partial Overview)

For advanced or inoperable disease, palliative locoregional and systemic strategies are central — including radiotherapy schedules and chemotherapy options for recurrent or metastatic presentations. The complete sequencing, applicable clinical trial pathways, and full regimen detail are available via the protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1017/S0022215116000499
  1. Larger lesions of the lip require more consideration with regard to reconstruction techniques.
  2. The five-year crude survival rates for surgical treatment are about 75–80 per cent for T1 to T2 tumours, dropping to 40–50 per cent for T3 and T4 tumours.
  3. Palliative RT may be used, either over short fractionation schedules or split course, for patients with advanced and inoperable disease, or those who are not fit for a more toxic, radical approach.
  4. Palliative chemotherapy should be considered for inoperable, recurrent and or metastatic disease, when possible patients should be offered entry to clinical trials.
View source ↗